Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

By C. Cannon, M. Blazing, R. Giugliano, A. McCagg, Jennifer A. White, P. Théroux, H. Darius, B. Lewis, T. O. Ophuis, J. Jukema and 11 more. New England Journal of Medicine, 2015

2,926 citations recorded by the source corpus.

Subfields: Cancer Research, Surgery

View Paper: https://www.semanticscholar.org/paper/04e339051fad2d12565c03cc49ccd939c7728590

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Marja-Riitta Taskinen
2. J. Liao
3. I. Graham
4. Massimo F. Piepoli
5. T. Ivanova
6. S. Daniels
7. S. Tsimikas
8. S. Grundy

In Surgery

1. I. Graham
2. S. Tsimikas
3. Marja-Riitta Taskinen
4. J. Liao
5. G. Bakris
6. Massimo F. Piepoli
7. T. Ivanova
8. A. Goldfine

Citations in the corpus

• 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. (2016, background): “The results of IMPROVE-IT, 61 are of major signi fi cance for a number of reasons.”
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, positive): “It must be stressed, however, that the only combination that has evidence of clinical benefit (one large RCT) is that of a statin combined with ezetimibe [353].”
• Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes (2016, background): “3 mmol/L (50 mg/dL) or greater or for those who cannot tolerate high-intensity statin therapy (41) (A rating).”
• A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. (2017, methodology): “For example, in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (59), after a median of 6 years of follow-up, the major adverse cardiac event (MACE) rate was 32.”
• National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015, methodology): “In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), 18,144 patients (approximately 24% women) with acute coronary syndrome ,10 days were randomized to simvastatin 40 mg daily plus ezetimibe 10 mg or placebo.(370) The primary outcome endpoint was a composite of c”